Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.

Frederick J RaalNyda FourieRussell ScottDirk BlomMatthys De Vries BassonMeral KayikciogluKate CaldwellDavid KallendEvan Steinnull null

Published in: European heart journal (2023)

Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.

Keyphrases

binding protein
phase iii
early onset
low density lipoprotein
clinical trial
open label
study protocol
phase ii
double blind
placebo controlled